As a new-type foreign trade service provider driven by technological transformation and foreign trade business, HiSiaddi has established a "1+2+3+4=1" service system, and can supply Fmoc-8-amino-3,6-dioxaoctanoic acid (Semaglutide side chain intermediate) sourced from multiple well-known original manufacturers.
As a research-and-development-oriented foreign trade enterprise, HiSiaddi has repeatedly provided product formulation optimization plans and application improvement suggestions for Fmoc-8-amino-3,6-dioxaoctanoic acid (Semaglutide side chain intermediate) through technological transformation cooperation with manufacturers and precise insight into market demands. Below is the formulation optimization consulting case of HiSiaddi for this product.
For inquiries regarding formulation optimization consulting services, please contact HiSiaddi customer service.
The client is France Peptide SAS, a high-end pharmaceutical enterprise headquartered in Lyon, France, specializing in R&D and commercial production of long-acting GLP-1 peptide drugs, supplying premium medical institutions and pharmaceutical R&D centers across the EU, and strictly following EMA, FDA and ICH Q7 quality standards. The enterprise purchases Fmoc-8-amino-3,6-dioxaoctanoic acid year-round as a core intermediate for Semaglutide side chains with an annual procurement volume of 130kg for solid-phase peptide synthesis mass production lines, representing a typical high-end pharmaceutical raw material procurement scenario.
The client previously purchased this intermediate via HiSiaddi, and all indicators met factory release specifications. However, multiple technical abnormalities emerged after feeding raw materials into workshop synthesis processes, including reduced production line yields and excessive impurities, which persisted despite repeated adjustments of reaction formulas and operating parameters by the internal R&D team, severely disrupting production progress and product compliance. The client immediately entrusted HiSiaddi with full-process root cause analysis and deliverable solution provision.
HiSiaddi formed a special team covering organic synthesis, peptide process and quality analysis, conducting traceability analysis combining raw material COAs, the client’s reaction system and workshop operating conditions, and identifying four core problems and their root causes:
The client adopted a traditional condensation system for side chain grafting reactions, with measured reaction conversion rates 9% lower than standard process values, accompanied by prominent di-Fmoc protected impurities and isomer impurities in chromatograms. Root causes: trace polar by-products remaining in raw materials altered the microenvironment of the reaction system; additionally, the intermediate contains a dioxaether chain structure with large steric hindrance, and the original condensation reagent exhibited insufficient activity, easily triggering incomplete coupling reactions.
In conventional DMF reaction solvent, powder of this intermediate tended to clump, with fine flocs remaining after prolonged stirring, increasing filtration load and inducing uneven local reaction concentrations. On one hand, uneven crystal morphology and broad particle size distribution of raw materials generated excessive fine powder; on the other hand, the client’s single original solvent system had mismatched polarity with this ether derivative, exacerbating molecular aggregation.
After batch storage, re-inspection upon factory arrival revealed gradual elevation of single impurities and minor deprotection of Fmoc groups. Root causes: trace acidic solvents remained in raw materials, paired with inadequate moisture-proof and light-shielding packaging protection, inducing slow degradation during ambient-temperature transit and temporary storage; meanwhile, open feeding operations in the workshop prolonged exposure to air and moisture, accelerating impurity formation.
Different batches of raw materials required repeated fine-tuning of reaction temperature, pH and material ratios after feeding, making it impossible to establish standardized operating parameters for production lines. The core cause lay in broad internal control ranges for residual solvents, water content and crystal forms in upstream production, leading to inconsistent batch performance incompatible with the client’s high-precision continuous production requirements.
HiSiaddi adopted a closed-loop solution integrating upstream raw material production rectification, downstream formulation system optimization, on-site operation specification adjustment and long-term quality control, completing full-process verification within 22 days to completely resolve all abnormalities.
Cooperated with domestic GMP factories to adjust targeted production and post-treatment procedures:
· Upgraded refining processes by adding weak alkaline washing and secondary recrystallization steps to fully remove di-protection by-products and polar impurities generated during synthesis, stabilizing single impurities below 0.04%;
· Optimized drying and desolvation parameters with segmented negative-pressure drying to strictly control residual solvents and water content, avoiding Fmoc group degradation triggered by residual acidic substances;
· Adjusted crystallization and screening workflows to unify crystal morphology and particle size distribution, reducing the proportion of ultrafine powder and improving powder flow and dissolution performance;
· Tightened internal control standards for all indicators to narrow inter-batch fluctuations and guarantee consistent performance of each raw material batch.
Minor adjustments to the reaction system were implemented without modifying the client’s core process framework to match raw material characteristics:
· Replaced conventional condensation reagents with Oxyma Pure composite systems compatible with high steric hindrance structures to boost coupling reaction activity and inhibit side reactions, restoring reaction conversion rates to standard levels;
· Modified dissolution solvents by blending a small amount of dichloromethane into DMF to optimize mixed solvent polarity, fully eliminating powder agglomeration and flocculation and reducing filtration loss simultaneously;
· Precisely regulated reaction parameters, providing fixed reaction temperature, system pH and material feeding molar ratios in a standardized parameter table to eliminate repeated adjustments batch-by-batch.
· Packaging upgrade: Thickened vacuum aluminum foil bags plus light-proof moisture-proof outer cartons with built-in desiccants and inert gas sealing to block moisture and light and extend stable storage life of materials;
· Special storage and transportation guidelines were formulated, specifying full-process cold-chain light-shielded transportation and low-temperature sealed temporary storage in workshops; feeding workflows were optimized to shorten open-air exposure time of raw materials and avoid air-induced degradation.
· Additional solubility and reaction activity simulation tests were performed for each batch before shipment to screen abnormal raw materials in advance;
· A complete set of English technical guidelines was provided to the client, covering material properties, dissolution methods, recommended process parameters and storage precautions, with updated COAs, spectra and stability data synchronized;
· Technical personnel were arranged for remote docking to regularly track production line operation and respond to process fine-tuning demands promptly.
1.
Full Recovery of Production Indicators After optimization, coupling reaction conversion rates returned to process standards, all by-products and degradation impurities were controlled within pharmacopoeia limits; materials dissolved uniformly without agglomeration, filtration loss decreased by 7%, and continuous multi-batch production operated stably with standardized production line parameters.
2.
3.
Greatly Improved Material Stability Under specified storage conditions, impurity growth rates of raw materials approached zero, and Fmoc protecting group stability met EU long-term storage requirements, smoothly passing EMA quarterly sampling inspections.
4.
The client’s process director stated that the root causes of this issue spanned raw material production and end-user application links. HiSiaddi accurately identified hidden risks and delivered a full set of implementable solutions balancing technical professionalism and pharmaceutical compliance requirements.
Both parties further deepened cooperation, with annual procurement volume increased to 160kg. The client entrusted HiSiaddi with overall supply and technical process support for this intermediate and multiple ether-chain side chain raw materials, establishing a long-term stable strategic partnership.
Fmoc-8-amino-3,6-dioxaoctanoic acid, an Fmoc-protected side chain intermediate containing ether chains, features large steric hindrance, susceptibility to degradation and high sensitivity to solvents and impurities. For solid-phase peptide synthesis production lines of high-end European pharmaceutical enterprises, raw material batch consistency, dissolution performance, residual impurities and process compatibility directly determine production yields and pharmaceutical compliance.
This issue was not a single-link failure but a comprehensive problem induced by superposition of raw material production, formulation systems and operating specifications. Drawing on full-industry-chain technical experience covering upstream and downstream links, HiSiaddi delivered a closed-loop solution by rectifying raw material quality at the source while optimizing end-user application processes, alongside standardized storage, transportation and operating protocols. It not only helped the client rapidly resume normal production and mitigate quality compliance risks, but also consolidated the supply chain competitiveness of domestic high-end pharmaceutical intermediates in high-end European markets via robust technical service capabilities.
For inquiries regarding formulation optimization consulting services, please contact HiSiaddi customer service.
+86-13120989737 
info@hisiaddi.com 
English
